title: FGF21 mimetic shows therapeutic promise.
abstract: FGF21 is a protein with multiple metabolic actions, currently a bright star beckoning on the metabolic disease therapeutic horizon. Gaich et al. (2013) present the first clinical efficacy trial for an FGF21 mimetic, finding robust lipid-lowering effects, some reduction in body weight, but surprisingly modest effects on glucose homeostasis.
authors.affiliation: Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD 20892, USA. Electronic address: marc.reitman@nih.gov.
authors.forename: Marc L
authors.initials: ML
authors.lastname: Reitman
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009765:Obesity / Q000188:drug therapy*
chemical_list: C585266:LY2405319; D005346:Fibroblast Growth Factors